Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemfibrozil in Predementia Alzheimer's Disease
NCT02045056Phase 1Completed
- Start
- May 2014
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gemfibrozil with Placebo (2 arms). Primary endpoints: Safety at 52 weeks, microRNA-107 levels at 48 weeks and 1 more. Started May 2014; status: completed.
02
Drugs
gemfibrozil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02045056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045056.